15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Prelude Therapeutics Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $6.00 to $9.00, a moderate spread. The average target of $7.67 sits 51% above the current $5.08. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.75 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Prelude Therapeutics Inc.
As of Sep, 3 of 3 firms rate PRLD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PRLD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.14 – $-0.14 · 1 analysts · -30% YoY
Next period, 1 analysts expect Prelude Therapeutics Inc to earn $-0.14 a share (range $-0.14 – $-0.14), versus $-0.20 a year earlier. Full-year consensus is $-0.54, growing to $-0.75 the year after.
REVENUE · NEXT QUARTER
$2.8M
Range $0 – $5.7M · 1 analysts · -50% YoY
Revenue is expected to reach $2.8M (range $0 – $5.7M), -49.6% year-over-year. Full-year consensus is $66.1M, rising to $56.7M next year.
Top analysts covering Prelude Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRLD.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$8.00+57.6% to target
Overall win rate
41%
+ Follow
#2
Reni J. Benjamin
JMP Securities · Rank #366
Buy
$6.00+18.2% to target
Overall win rate
32%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #416
Buy
$9.00+77.3% to target
Overall win rate
22%
+ Follow
#4
Reni J. Benjamin
Citizens
Buy
$6.00+18.2% to target
Coverage
—
+ Follow
PRLD stock forecast FAQ
What is PRLD's average 12-month price target?+
The 3 analysts with a live target average $7.67 for Prelude Therapeutics Inc over the next 12 months, ranging from a $9.00 high to a $6.00 low.
Is PRLD stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PRLD?+
The Street-high target is $9.00 (D. Boral Capital), and the Street-low is $6.00 (Citizens). The average of all 3 active targets is $7.67.
How many Wall Street analysts cover PRLD?+
3 analysts have an active rating on Prelude Therapeutics Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering PRLD?+
Among analysts who currently cover PRLD, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #199). Their current call is Buy with a $8.00 target.
What is Prelude Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.14 – $-0.14) across 1 analysts. Full-year EPS is projected at $-0.54, rising to $-0.75 the following year.
How much revenue is Prelude Therapeutics Inc expected to report next quarter?+
Consensus revenue is $2.8M (range $0 – $5.7M). Full-year revenue is projected at $66.1M, growing to $56.7M next year.
Have analysts been upgrading or downgrading PRLD lately?+
As of Sep, 3 of 3 firms rate PRLD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRLD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
